AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Shares of AbbVie Inc. ABBV slipped 2.40% to $182.31 Friday, on what proved to be an all-around positive trading session for ...

AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

This Big Pharma stock is one of the safest bets, according to the Mad Money host, and it plays an attractive dividend to ...

ABBV stock is up 7% in morning trading on the strength of its two blockbuster immunology drugs Skyrizi and Rinvoq. They are expected to produce combined sales of $31 billion in 2029.